EUVIMEDEUVIMED entdecken
Crossref

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity

Lai Yue Chan iD, Benjamin D Weger, Meltem Weger, Junqiao Du, Nicole Lawrence, Marlon H Cardoso iD, Samilla B de Rezende, Jéssica A I Muller, Kuok Yap iD, Brian W C Tse, Kamil A Sokolowski, Robert K P Sullivan und 4 weitere

Journal of the American Chemical Society · 2025

DOI: 10.1021/jacs.5c05536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Lai Yue Chan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University o…. Hauptthemen laut MEDLINE: Obesity, Peptides, Repressor Proteins, Anti-Obesity Agents. Die Arbeit nennt 82 Literaturangaben. Gefördert von: Fundação de Apoio à Pesquisa do Distrito Federal, Advance Queensland, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity stands as a global epidemic and is the primary risk factor for type 2 diabetes, ranking as the fifth leading cause of death worldwide. While lifestyle changes can address body fat accumulation, pharmacotherapies can also assist in sustained weight loss. Here, we report the design of a new generation of prohibitin peptide-based therapeutics engineered to target white adipose tissues. These peptides demonstrate significant reduction of body weight in a high-fat diet-induced obesity mouse model and represent a paradigm shift in approaches to the treatment of obesity by inducing mitochondrial uncoupling. The most potent compound, PTP-r, was prohibitin-TP01 substituted with d-arginine. Overall, the study reveals the promising development of next-generation adipose-targeting prohibitin peptides, capable of curbing adipocyte expansion and body weight, with favorable preclinical safety profiles. These peptides hold immense potential for developing new treatments to address obesity and metabolic syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityPeptidesRepressor ProteinsAnti-Obesity AgentsAnimalsProhibitinsMiceDiet, High-FatMice, Inbred C57BLMaleHumans

Substanzen

ProhibitinsPeptidesRepressor ProteinsAnti-Obesity Agents

Autor:innen und Institutionen

  • Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • Institute for Molecular Bioscience, Centre for Cell Biology and Chronic Disease, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul 79117900, Brazil.
  • S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul 79117900, Brazil.
  • Preclinical Imaging Facility, Translational Research Institute, Brisbane, Queensland 4102, Australia.
  • Queensland Brain Institute, The University of Queensland, Brisbane, Queensland 4072, Australia.

ORCID-Profile: Lai Yue Chan, Marlon H Cardoso, Kuok Yap, Octávio L Franco, David J Craik

Förderung

  • Fundação de Apoio à Pesquisa do Distrito Federal
  • Advance Queensland
  • Alzheimer's Association
  • National Health and Medical Research Council
  • Australian Research Council
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • National Institute on Aging
  • Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul

Zitieren

APA

Chan, L. Y., Weger, B. D., Weger, M., Du, J., Lawrence, N., Cardoso, M. H., de Rezende, S. B., Muller, J. A. I., Yap, K., Tse, B. W. C., Sokolowski, K. A., Sullivan, R. K. P., Gunter, J., Franco, O. L., Gachon, F., & Craik, D. J. (2025). Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c05536

Vancouver

Chan LY, Weger BD, Weger M, Du J, Lawrence N, Cardoso MH, et al. Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c05536

BibTeX
@article{Chan2025,
  author = {Chan, Lai Yue and Weger, Benjamin D and Weger, Meltem and Du, Junqiao and Lawrence, Nicole and Cardoso, Marlon H and de Rezende, Samilla B and Muller, Jéssica A I and Yap, Kuok and Tse, Brian W C and Sokolowski, Kamil A and Sullivan, Robert K P and Gunter, Jennifer and Franco, Octávio L and Gachon, Frédéric and Craik, David J},
  title = {Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  doi = {10.1021/jacs.5c05536}
}
Kostenlos starten →